Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently announced that the first patient has been dosed with the PKM2 activator, TP-1454, in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors. “Dosing the first patient in this study marks an important milestone, as TP-1454 is the first PKM2 activator to be […]
The 11th annual Utah Life Sciences Summit (ULSS) Nov. 9-11, went virtual this year. But despite the physical distance, the ULSS made news and ignited our life sciences industry with a special announcement — the launch of BioHive, a new bold campaign to brand and expand Utah’s life sciences ecosystem. ICYMI…view the video and see […]
Transit Scientific’s new FDA cleared XO Score system was successfully used to dilate multiple challenging fibrotic and calcific lesions in hemodialysis patients with stenotic and occluded fistulas. Dr. Richard Saxon, FSIR and member of the SDI Medical Group, while working at Tri City Medical Center Medical Center, Oceanside, California, USA performed the first procedures using […]
Article courtesy of BusinessWire Local leaders to create ecosystem for innovation, job creation, and growth SALT LAKE CITY–(BUSINESS WIRE)–Since 2012, Utah’s life sciences community has grown faster than any other in the country. Through collective efforts of the more than 1,100 life sciences-related companies (and growing), it intends to continue that trend and join the […]
Logan, UT, October 28, 2020 – Quansys Biosciences announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its laboratory-based IgG antibody test. A positive IgG antibody result identifies patients who have been exposed to the SARS-CoV-2 virus and, as part of their recovery, demonstrated an adaptive […]
Utah’s own life sciences entrepreneur, Dinesh C. Patel, PhD, has been honored with the Utah Governor’s Lifetime Achievement Medal for Science and Technology for his contribution in the field of biotechnology and pharmaceuticals. “This honor is well-deserved,” said Kelvyn Cullimore, president and CEO of BioUtah. “Dr. Patel has been instrumental in founding and bringing a […]
Sanofi and the Parkinson’s Foundation announced on Wednesday a new research collaboration to advance the availability of genetic testing and counseling for people with Parkinson’s disease in the U.S. Over the next two years, Sanofi will provide $1 million in research funding to support the PD GENEration Mapping the Future of Parkinson’s Disease initiative. The […]
On October 7, the SBA released updated FAQs (question #52) to clarify that lenders must recognize the extended deferral period for payments on the principal, interest, and fees on all PPP loans, even if the initial loan terms indicates a six-month deferral (the initial period when the program was first enacted). Under the Paycheck Protection […]
Utah-based IDbyDNA announced yesterday that, in an effort to help labs better identify respiratory pathogens and avoid overuse of antimicrobial drugs, IDbyDNA and Illumina, Inc. are co-launching the new Respiratory Pathogen ID/AMR Target Enrichment Assay. The test, currently for research use only, will improve testing for infectious diseases, including COVID-19, and will leverage IDbyDNA’s Explify® […]
Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently announced that the first patient has been dosed with the PKM2 activator, TP-1454, in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors. “Dosing the first patient in this study marks an important milestone, as TP-1454 is the first PKM2 activator to be […]
On Wednesday, Governor Herbert announced the state’s new response plan to COVID-19, effective October 15. This updated plan utilizes a COVID-19 Transmission Index and replaces the previous color-coded guidance system of red, orange, yellow and green. The new approach comes at a time when the state has seen a significant spike in infection rates. The […]
CAMBRIDGE, Mass., October 9, 2020 – Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed with TP-1454, an investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, administered alone and in combination with ipilimumab and nivolumab, in a Phase 1/1b study in patients with advanced […]